<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80722">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02056847</url>
  </required_header>
  <id_info>
    <org_study_id>JW-PTV-713</org_study_id>
    <nct_id>NCT02056847</nct_id>
  </id_info>
  <brief_title>to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia</brief_title>
  <acronym>SIPHON</acronym>
  <official_title>Randomized, Open-label, Multi-centered Study to Evaluate the Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia(Phase 4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Catholic Univ. of Korea Daejeon St. Marys Hostpial</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea Yeouido St.Marys Hostpial</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea Uijeongbu St.Marys Hostpial</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospitla</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dong-A University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Youngnam University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eulji University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chunnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanllym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective

      : To evaluate that there is no different effect on HbA1c between routine lipid lowering
      therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic
      patients with impaired fasting glucose (IFG).

      H0: µT-µC ≥ 0.4 vs H1: µT-µC &lt; 0.4

      µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in
      the control drug (Pitavastatin 2 MG)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigational Product Test group: Pitavastatin calcium (LIVALO) 4mg tab Control group:
      Pitavastatin calcium (LIVALO) 2mg tab

      Study Site: Multi-centers in Korea

      Period: For 24months after IRB approval at each site (Including 12months of subject
      enrollment period)

      Efficacy End points

      A. Primary end point The change of HbA1c before and after taking LIVALO

      B. Secondary end point

        1. Incidence of diabetes within 1year after registration (based; FPG ≥126mg/dL or to need
           taking diabetes medication)

        2. Incidence of major cardiovascular (TLR-MACE) events within 1 year after registration

        3. Incidence of total cardiovascular (TVR-MACE) events within 1 year after registration

        4. The change of the lipid composition (T-chol, TG, LDL-C, HDL-C, ApoA1/ApoB)

        5. The changes of hs-CRP

        6. The changes of Adiponectin

        7. The change of blood glucose and Insulin levels FPG(Fasting Plasma Glucose) Fasting
           Serum Insulin HOMA IR [fasting insulin(µIU/mL) X fasting glucose(mg/dL)]/405 HOMA β
           [360 X fasting insulin(µIU/mL)]/[fasting glucose(mg/dL)-63]

      Statistical Methods

        1. Efficacy A. Primary efficacy endpoint analysis Describe statistics of basic about the
           HbA1c variation before and after taking LIVALO by groups. In order to verify
           noninferiority of test drug, check that upper limit of confidence interval of the
           one-sided 97.5% is less than 0.4% about difference of HbA1c variation between the
           control group and the test group, before and after taking LIVALO.

           B. Secondary efficacy endpoint analysis Continuous variables

           :Present the mean, standard deviation, minimum, and maximum values for TC, TG, LDL-C,
           HDL-C, Fasting serum insulin, Fasting plasma glucose and HOMA IR, HOMA β etc. by each
           visit and in each group. In comparison with intergroup, using two-sample t-test for
           normal distribution and using Wilcoxon rank sum test for non-normal distribution. Also
           In comparison with the same group, using paired t-test for normal distribution and
           using Wilcoxon signed rank test for non-normal distribution.

           Discrete variables

           : The number and percentage of the subjects for incidence of DM and cardiovascular
           event are described of each group and the ratio of the intergroup comparison use
           χ2-test or Fisher's exact test.

        2. Safety All the AEs and the ADRs which manifested more than once  are described by the
           frequency and percentage of each group and   use χ2-test or Fisher's exact test for
           intergroup comparison about the rate of AEs and ADRs Laboratory tests and vital signs
           are analyzed descriptive statistics quantity of each group, and in comparison with
           intergroup, use two-sample t-test for normal distribution and use Wilcoxon rank sum
           test for non-normal distribution. Also, In comparison with the same group, use paired
           t-test for normal distribution and use Wilcoxon signed rank test for non-normal
           distribution.

      Clinical laboratory test is analyzed the frequency and percentage of the outside normal
      range of subjects, and using χ2-test or Fisher's exact test with intergroup.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The change of HbA1c before and after taking LIVALO®</measure>
    <time_frame>24 weeks after taking IP</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of diabetes</measure>
    <time_frame>within 1year after registration</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>based; FPG ≥126mg/dL or to need taking diabetes medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of total cardiovascular (TVR-MACE) events</measure>
    <time_frame>within 1 year after registration</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of the lipid composition (T-chol, TG, LDL-C, HDL-C, ApoA1/ApoB)</measure>
    <time_frame>24weeks and 1 year after registration</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of hs-CRP, Adiponectin, blood glucose and Insulin levels</measure>
    <time_frame>24weeks and 1 year after registration</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The change of blood glucose and Insulin levels FPG(Fasting Plasma Glucose) Fasting Serum Insulin HOMA IR [fasting insulin(µIU/mL) X fasting glucose(mg/dL)]/405 HOMA β [360 X fasting insulin(µIU/mL)]/[fasting glucose(mg/dL)-63]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>HbA1c Level Associated With Lipid Compositions</condition>
  <arm_group>
    <arm_group_label>Pitavastatin calcium 4mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pitavastatin calcium (LIVALO®) 4mg, once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pitavastatin calcium 2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pitavastatin calcium (LIVALO®) 2mg, once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin calcium 4mg</intervention_name>
    <description>taking once a day</description>
    <arm_group_label>Pitavastatin calcium 4mg</arm_group_label>
    <other_name>Pitavastatin calcium(LIVALO) 4mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin calcium 2mg</intervention_name>
    <description>Taking once a day</description>
    <arm_group_label>Pitavastatin calcium 2mg</arm_group_label>
    <other_name>LIVALO 2mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and Female patients who are more than 20 years old or 70 years old or less.

          2. Patient who voluntarily sign on written informed consent form

          3. Patient who LDL-C ≥ 100mg/dl or was diagnosed with hyperlipidemia

          4. Patient who was suspected with Imparied Fasting Glucose (IFG) and satisfy FPG level ≥
             100mg/dL and &lt; 126mg/dL when FPG measured twice.

        Exclusion Criteria:

          1. Patient who has familial hypercholesterolemia

          2. Patient who has been diagnosed with Type1, Type2 DM or secondary DM(diabetes
             mellitus) at the screening visit (Diagnostic criteria of DM: HbA1c≥ 6.5%)

          3. Patient who has received antidiabetic within 6weeks to the screening visit

          4. Patient who has been taking insulin continuously or to be needed in the future

          5. Patient who has a history of gastrectomy

          6. Patient who is suspected or diagnosed with malignant tumor within last 10 years

          7. Patient who has serious pancreatic disease or endocrine disorders

          8. Patient who currently takes Cyclosporine

          9. Patient who has a medical history of hypersensitivity to Pitavastatin calcium

         10. Patient who has suspected renal failure (serum creatinine ≥2.0 mg/dL)

         11. Patient who has suspected liver dysfunction (more than 2.5 times the upper limit of
             normal AST or ALT)

         12. Patient who has more than 3 times the upper limit of normal CPK

         13. Patient who is breastfeeding, pregnant or planning pregnancy

         14. Patient who deemed inappropriate as subject in the opinion of the Principal
             Investigator or Investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NamSik Chung, M.D., Ph D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HyoJeong Seo</last_name>
    <phone>82-2-840-6958</phone>
    <email>hjseo@jw-pharma.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SongHee Cho</last_name>
    <phone>82-2-840-918</phone>
    <email>20130594@jw-group.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>JW pharmaceutical</name>
      <address>
        <city>Seoul</city>
        <zip>137-864</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HyoJeong Seo</last_name>
      <phone>82-2-840-6958</phone>
      <email>hjseo@jw-pharma.co.kr</email>
    </contact>
    <contact_backup>
      <last_name>SongHee Cho</last_name>
      <phone>82-2-840-6918</phone>
      <email>20130594@jw-pharma.co.kr</email>
    </contact_backup>
    <investigator>
      <last_name>SungHo Her, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>PumJoon Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>WooBaek Chung, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>JongMin Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>WooShik Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SeungWoon Rha, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>JongSung Park, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>DongJu Choi, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>HyeonCheol Gwon, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>HaeYoung Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SoYeon Choi, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>BumKee Hong, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Namsik Chung, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>JongSeon Park, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>EunSeok Shin, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>KyungTae Jung, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>KiHoon Han, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MyungHo Jeong, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>JeiKeon Chae, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SiWan Choi, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>KyooRok Han, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>February 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Livalo, pitavastatin, hyperlipidemia, IFG</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
